5 Exhibitors to Visit at AMWC China 2026

Paid placement disclosure. These exhibitor sections are paid Shared Spotlight placements. Inclusion is not an award, ranking, or TradeShowIntel endorsement, and it does not affect independent Floor Picks.Disclosure version 2026-09

Why plan your AMWC China floor time before you arrive

AMWC China runs October 16 to 18, 2026 at the Wuzhouqing Convention and Exhibition Center in Chengdu, a large-format venue that combines a scientific congress program with a commercial exhibition floor. Attendees balancing plenary sessions, workshops, and exhibit time routinely find that unplanned floor walks leave key stands unvisited by the close of day three.

The five companies featured in this Shared Spotlight, Allergan Aesthetics, Galderma, 科医人 (Lumenis), 复锐医疗科技(天津)有限公司 (Sisram Medical), and 巨子生物 (Giant Biogene), collectively span neuromodulators, HA fillers, PLLA biostimulators, laser and IPL capital equipment, multi-modality energy platforms, and recombinant collagen dressings. Visiting them in sequence gives a buyer a practical cross-section of the categories most active at this show without doubling back across the hall.

Why these exhibitors

A set built around the core buying jobs at AMWC China

Aesthetic physicians building a multi-category treatment menu will find relevant products at Allergan Aesthetics and Galderma, both of which carry NMPA-recognized portfolios covering neuromodulators, fillers, and biostimulators. Clinic directors and procurement leads evaluating capital equipment will find distinct platform approaches at 科医人 and 复锐医疗科技(天津)有限公司, one focused on laser and IPL with China service infrastructure, the other on multi-modality energy devices combined with injectable and wellness programs. Dermatologists and buyers sourcing post-procedure or regenerative skincare will find a differentiated ingredient story at 巨子生物. These five stands do not cover every exhibitor at the show, but they address a coherent set of purchasing decisions a single buyer might be advancing simultaneously.

How to use this Shared Spotlight

Download the exhibitor map before day one Wuzhouqing is a multi-hall venue. Confirm booth locations on the official AMWC China floor plan at amwcchina.com as soon as it is published, then mark each of the five stops on a printed or digital copy before you enter the hall.
Anchor to the injectable cluster first Allergan Aesthetics and Galderma are the two largest injectable portfolios in this set. Visiting them consecutively lets you compare neuromodulator, HA filler, and biostimulator offerings while the details of each conversation are still fresh.
Block device time separately Energy-based device demonstrations at 科医人 and 复锐医疗科技(天津)有限公司 often involve live equipment and queues. Schedule those visits during mid-morning or mid-afternoon when foot traffic is lighter and demonstration slots are more available.
Close the route at 巨子生物 The Giant Biogene stand covers post-procedure dressings and recombinant collagen ingredients, a category that complements the treatment protocols discussed at the injectable and device stands. Visiting it last allows you to ask suppliers about compatibility with products you have already evaluated.

Floor-planning tip Reserve a 90-minute block on day one for the two injectable stands and a separate 90-minute block on day two for the two device stands, leaving the Giant Biogene visit as a 30-minute closing stop before the afternoon session begins.

TL;DR

5 stops worth planning

Suggested floor route

Injectable stands first, device platforms second, regenerative skincare last

Starting with Allergan Aesthetics and Galderma while the injectable category is fresh, then moving to 科医人 and 复锐医疗科技(天津)有限公司 for device evaluations, and finishing at 巨子生物 minimizes directional backtracking and keeps related conversations grouped by product category.

1Allergan AestheticsPrioritize this stand if you are an aesthetic physician, dermatologist, or clinic operator in China building or expanding a multi-category injectable and body contouring treatment menu under recognized brand franchises.
2GaldermaPrioritize this stand if you are an aesthetic physician or dermatologist in China seeking to add a NMPA-approved PLLA biostimulator to your practice alongside an established HA filler and neuromodulator line.
3科医人Prioritize this stand if you are a clinic director or aesthetic physician evaluating laser or IPL capital equipment with China-based service and regulatory support.
4复锐医疗科技(天津)有限公司Prioritize this stand if you are a clinic director or procurement lead evaluating multi-modality energy-based platforms or combined device-plus-injectable programs with local China support.
5巨子生物 (Giant Biogene)Prioritize this stand if you are a dermatologist, aesthetic clinic buyer, or distributor sourcing Class II post-procedure dressings or recombinant collagen ingredients with documented regulatory and clinical backing.

Allergan Aesthetics

Developer and marketer of a medical aesthetics portfolio spanning facial injectables, body contouring, breast aesthetics (plastics), and skin care.

Read company profilePrioritize this stand if you are an aesthetic physician, dermatologist, or clinic operator in China building or expanding a multi-category injectable and body contouring treatment menu under recognized brand franchises.Read more

About

Allergan Aesthetics, an AbbVie company, is headquartered in Irvine, California, and operates across more than 100 countries with approximately 6,000 employees. The business was established as a dedicated aesthetics unit in 2020 following AbbVie's acquisition of Allergan, which was founded in 1948. Its portfolio spans four categories: facial injectables under the BOTOX® Cosmetic and JUVÉDERM® Collection brands, non-invasive body contouring via CoolSculpting®, breast aesthetics, and the SkinMedica® physician-dispensed skin care line.

The company reported approximately $5.2 billion in revenue in 2024 and supports product development through 11 R&D sites worldwide. SKINVIVE by JUVÉDERM®, an HA microdroplet skin booster, expanded into 57 markets in 2025, including 35 new markets added that year. A premarket approval application for a neck-appearance indication was accepted by the U.S. FDA in mid-2025. For practitioners in China, the combination of a recognized neurotoxin franchise, a broad HA filler collection, and an expanding skin booster product positions Allergan Aesthetics as a multi-category partner for clinic and med-spa treatment menus.

SKINVIVE by JUVÉDERM® is an injectable version of hyaluronic acid, a naturally occurring molecule found in the skin and important for skin hydration. — Darin Messina, Ph.D., Senior Vice President, Aesthetics R&D, AbbVie

At AMWC CHINA - AESTHETIC & ANTI-AGING MEDICINE WORLD CONGRESS 2026

Allergan Aesthetics is confirmed as a sponsor and exhibitor at AMWC China 2026 through its Shanghai subsidiary, 艾尔建医疗器械（上海）有限公司. The company's presence at a congress focused on injectable products, anti-aging medicine, and combination treatment protocols makes it a natural destination for practitioners seeking to discuss the BOTOX® Cosmetic neuromodulator range, the full JUVÉDERM® Collection of hyaluronic acid fillers, and the SKINVIVE by JUVÉDERM® skin booster. No specific product launches or structured demos for the China edition were disclosed in available sources ahead of the event.

BOTOX® Cosmetic (onabotulinumtoxinA) for glabellar, forehead, lateral canthal lines, and platysma bandsJUVÉDERM® Collection including VOLUMA® XC, VOLBELLA® XC, and SKINVIVE® for cheek, lip, chin, temple, and under-eye correctionSKINVIVE by JUVÉDERM® expansion to 57 markets in 2025 and pending neck-indication FDA reviewCoolSculpting® cryolipolysis for non-invasive localized fat reductionSkinMedica® cosmeceutical skin care for practitioner-dispensed anti-aging protocolsNeuromodulatorHA FillerSkin BoosterBody Contouring

Why visit

Prioritize this stand if you are an aesthetic physician, dermatologist, or clinic operator in China building or expanding a multi-category injectable and body contouring treatment menu under recognized brand franchises.

What to ask at the booth

Which JUVÉDERM® Collection products and BOTOX® Cosmetic indications are currently registered and available in China?
What training and injection technique support do you offer Chinese practitioners for your injectable portfolio?
Can you share clinical or real-world outcome data on SKINVIVE by JUVÉDERM® relevant to Asian skin types?
What is the expected China availability timeline for the SKINVIVE by JUVÉDERM® neck-appearance indication?
How does CoolSculpting® fit a China-focused med-spa or clinic business model in terms of device access and economics?

Galderma

Pure-play dermatology category leader spanning Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.

Read company profilePrioritize this stand if you are an aesthetic physician or dermatologist in China seeking to add a NMPA-approved PLLA biostimulator to your practice alongside an established HA filler and neuromodulator line.Read more

About

Galderma Group AG, headquartered in Zug, Switzerland and founded in 1981, is a pure-play dermatology company operating across three segments: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Its portfolio spans neuromodulators (Dysport), hyaluronic acid fillers (Restylane), poly-L-lactic acid biostimulators (Sculptra), and the sensitive-skin skincare brand Cetaphil. The company employs more than 7,600 people and is present in approximately 90 countries.

Galderma recorded 5.207 billion USD in net sales for full-year 2025, up 17.7 percent at constant currency, and has secured more than 300 major regulatory approvals since 2020. In the China market specifically, Sculptra received NMPA approval on September 30, 2024, and launched in Shanghai in April 2025, making it a timely presence at a conference focused on biostimulators and regenerative aesthetics. Galderma also operates the GAIN (Global Aesthetic Injector Network) medical education program to support clinical training for injectors worldwide.

Galderma's strong performance in the first nine months of 2025 demonstrates the breadth of our portfolio and our ability to deliver growth through innovation, commercial excellence, and global expansion. With continued progress across science, education, and our full dermatology portfolio, Galderma is uniquely positioned to become the undisputed dermatology powerhouse. — Flemming Ørnskov, M.D., MPH, Chief Executive Officer, Galderma

At AMWC CHINA - AESTHETIC & ANTI-AGING MEDICINE WORLD CONGRESS 2026

Galderma is a recurring exhibitor at AMWC China and has been listed among participating brands at prior Chengdu and China editions of the congress. No specific booth number or demo schedule for the October 2026 Chengdu edition has been published by official sources. Given the event's focus on injectable aesthetics, anti-aging medicine, and regenerative medicine, visitors can expect representation of the full injectable portfolio, with particular relevance to Sculptra's recent NMPA approval and China market entry, Restylane formulations approved for the Chinese market, and Dysport for neuromodulator indications. Attendees interested in post-procedure skincare protocols may also find Cetaphil referenced in combination treatment discussions.

Sculptra (PLLA-SCA biostimulator): NMPA-approved September 2024, China launch April 2025Restylane HA filler family: multiple formulations differentiated by G-prime and longevity for specific facial areasDysport (abobotulinumtoxinA): neuromodulator for glabellar lines and facial wrinklesGAIN (Global Aesthetic Injector Network): structured training and certification program for injectorsCombined injectable and Cetaphil skincare protocols for Asian skin types and post-procedure careBiostimulatorHA FillerNeuromodulatorNMPA Approved

Why visit

Prioritize this stand if you are an aesthetic physician or dermatologist in China seeking to add a NMPA-approved PLLA biostimulator to your practice alongside an established HA filler and neuromodulator line.

What to ask at the booth

What is the current China indication and post-market plan for Sculptra, and which additional fillers or biostimulators are in the NMPA pipeline?
Which Restylane formulations are approved in China, and what differentiates them by G-prime or longevity for specific facial areas?
What training and certification does Galderma offer Chinese injectors through the GAIN program?
Can you share real-world Chinese patient data or study results comparing Sculptra and Restylane outcomes?
What combined injectable and Cetaphil skincare protocols do you recommend for Asian skin types and post-procedure care?

科医人

Energy-based aesthetic and medical devices

Read company profilePrioritize this stand if you are a clinic director or aesthetic physician evaluating laser or IPL capital equipment with China-based service and regulatory support.Read more

About

科医人 operates under the Lumenis brand in China, distributing and supporting a portfolio of energy-based devices used in aesthetic medicine, ophthalmology, and surgical applications. The company's Chinese-market presence is anchored at lumenis.com.cn, serving clinics and hospitals across the country.

Lumenis is recognized globally for its laser and intense pulsed light platforms, with technologies spanning CO2 fractional resurfacing, IPL photorejuvenation, and non-ablative treatments. For buyers at an aesthetic medicine congress, the relevant range covers skin resurfacing, pigmentation correction, body contouring, and women's health applications.

At AMWC CHINA - AESTHETIC & ANTI-AGING MEDICINE WORLD CONGRESS 2026

AMWC China draws aesthetic physicians, dermatologists, and clinic directors evaluating capital equipment and treatment protocols. 科医人's product scope, covering laser resurfacing, IPL, and minimally invasive energy-based platforms, maps directly to the clinical topics on the congress agenda. Visitors to the stand can expect to discuss device specifications, clinical evidence, and service support for the China market.

CO2 fractional laser resurfacing platformsIntense pulsed light systems for photorejuvenation and pigmentationNon-ablative and minimally invasive treatment optionsChina-market clinical support and service infrastructureEnergy-based women's health device applicationsLaser resurfacingIPLEnergy-based devicesAesthetic medicine

Why visit

Prioritize this stand if you are a clinic director or aesthetic physician evaluating laser or IPL capital equipment with China-based service and regulatory support.

What to ask at the booth

Which device lines are currently available and supported in the China market?
What clinical training and after-sales service does 科医人 provide to Chinese clinics?
Are there combination treatment protocols combining IPL and fractional laser on a single platform?
What financing or placement models are available for clinic buyers in China?
How does the company handle regulatory approval status for devices sold in China?

复锐医疗科技(天津)有限公司

Energy-based medical aesthetic devices (Alma portfolio) plus injectables and wellness solutions, operating as the China subsidiary of HKEX-listed Sisram Medical Ltd (01696).

Read company profilePrioritize this stand if you are a clinic director or procurement lead evaluating multi-modality energy-based platforms or combined device-plus-injectable programs with local China support.Read more

About

Sisram Medical (Tianjin) Limited is the wholly-owned PRC subsidiary of HKEX-listed Sisram Medical Ltd (01696), headquartered in Caesarea, Israel, and majority-controlled by Fosun Pharma. The group, which traces its device heritage to Alma Lasers founded in Israel in 1999, employs approximately 1,040 people across a portfolio spanning energy-based devices, injectables, and wellness solutions sold in more than 90 countries and regions.

Roughly 25.6 percent of group employees are R&D specialists, underpinning a product line that integrates multi-modality laser and energy platforms with injectable offerings such as the hyaluronic acid-based Profilo. The Tianjin subsidiary anchors Sisram's China localization strategy within the Fosun Pharma ecosystem, giving domestic clinics access to Alma's device portfolio alongside a developing injectable pipeline for the mainland market.

At AMWC CHINA - AESTHETIC & ANTI-AGING MEDICINE WORLD CONGRESS 2026

Sisram Medical is confirmed as a sponsor and exhibitor at AMWC China 2026 in Chengdu. Visitors can expect to see the company's energy-based device portfolio, including the Alma Harmony multi-modality anti-aging platform, the Soprano Titanium three-wavelength laser hair removal system, and the Opus skin resurfacing device, alongside injectable offerings such as Profilo. No specific demo schedule has been published ahead of the event, but the company's full scope of EBD and injectable products aligns directly with the show's focus on aesthetic and regenerative dermatology.

Alma Harmony: multi-modality platform addressing a range of skin concerns across skin typesSoprano Titanium: TrioMax handpiece combining 755 nm, 810 nm, and 1064 nm wavelengths for near-painless hair removalOpus: fractional plasma skin resurfacing and rejuvenationProfilo: injectable hyaluronic acid product for skin hydration and remodelingChina localization roadmap under the Fosun Pharma group structureEnergy-based devicesLaser hair removalInjectablesSkin resurfacing

Why visit

Prioritize this stand if you are a clinic director or procurement lead evaluating multi-modality energy-based platforms or combined device-plus-injectable programs with local China support.

What to ask at the booth

Which Alma devices are now manufactured locally in China, and what is the localization timeline?
What is the current status of the DAXXIFY injectable launch in mainland China?
What training, clinical support, and service coverage do you provide for clinics operating in China?
How does Soprano Titanium's TrioMax handpiece perform across different Fitzpatrick skin types?
What financing or placement programs are available for new clinics acquiring Alma platforms?

巨子生物 (Giant Biogene)

Developer and manufacturer of professional skin treatment products based on recombinant collagen and rare ginsenosides, including medical dressings and functional skincare.

Read company profilePrioritize this stand if you are a dermatologist, aesthetic clinic buyer, or distributor sourcing Class II post-procedure dressings or recombinant collagen ingredients with documented regulatory and clinical backing.Read more

About

Giant Biogene Holding Co., Ltd. (巨子生物) is headquartered in Xi'an, Shaanxi, China, and was founded in 2000. The company develops and manufactures bioactive ingredient-based products across three categories: professional skincare, Class II medical dressings, and functional foods. Its core brands include 可复美 (Comfy/Kefumei), a recombinant collagen medical dressing line for post-procedure repair; 可丽金 (COLEGKIN/Kelijin), a human-like collagen skincare series; and 欣苷 (SKIGIN) and 参苷 (Shenggan), built on proprietary rare ginsenoside synthesis. The company listed on the Hong Kong Stock Exchange in November 2022 (2367.HK), positioned as China's first publicly traded recombinant collagen company.

Giant Biogene holds the first patent granted in China for a recombinant collagen (类人胶原蛋白) production method, filed in 2005 and recognized with a China Patent Gold Award in 2016 and a National Technological Invention Award (2nd prize) in 2013. Its in-house synthetic biology platform produces more than 50 types of recombinant collagen, with 186 or more patents granted or applied for as of the latest reporting date. Interim 2025 revenue reached RMB 3.11 billion, a 22.5 percent year-over-year increase, reflecting demand from aesthetic clinics, distributors, and OEM partners sourcing recombinant collagen ingredients and finished products.

At AMWC CHINA - AESTHETIC & ANTI-AGING MEDICINE WORLD CONGRESS 2026

Giant Biogene has participated in prior editions of AMWC China, where it presented its recombinant collagen portfolio with a focus on the 可丽金 and 可复美 brand lines for skin rejuvenation and post-procedure repair. Booth assignment and confirmed participation for the October 2026 Chengdu edition had not been verified in official sources at the time of publication. Visitors with interest in Class II medical dressings, recombinant collagen ingredients, or ginsenoside-based dermocosmetics should check the official exhibitor directory or contact the company directly before the event.

可复美 (Kefumei) recombinant collagen Class II medical dressing for post-procedure wound repair可丽金 (COLEGKIN) human-like collagen skincare and mask series for anti-aging and barrier careProprietary synthetic biology platform with 50+ in-house recombinant collagen typesRare ginsenoside product lines 欣苷 (SKIGIN) and 参苷 (Shenggan) built on proprietary synthesis186+ patents granted or applied, including China's first recombinant collagen production method patentRecombinant collagenMedical dressingsRare ginsenosidesPost-procedure repair

Why visit

Prioritize this stand if you are a dermatologist, aesthetic clinic buyer, or distributor sourcing Class II post-procedure dressings or recombinant collagen ingredients with documented regulatory and clinical backing.

What to ask at the booth

Which of your recombinant collagen types are best suited for post-procedure medical dressings versus daily skincare?
What Class II medical device registrations and clinical data support the 可复美 dressing line?
Can you supply recombinant collagen bulk ingredients or OEM/ODM manufacturing for our own brand?
What international market certifications and distribution support do you offer for markets such as Canada, Japan, and the United States?
What is your minimum order quantity and lead time for the recombinant collagen library grades?

Before you leave the hall

Capture notes and follow up within 48 hours

After visiting all five stands, consolidate your notes on pricing tiers, regulatory status, and support terms while the conversations are recent. Each of these companies operates differently in the China market, so the details that distinguish them are worth recording before the next day's sessions begin.

For a full exhibitor list, session schedule, and venue map, visit the official event site at amwcchina.com. For additional exhibitor profiles and floor guides for AMWC China 2026, see the TradeShowIntel event page linked below.

AMWC China 2026 on TradeShowIntel Official AMWC China website

Frequently asked questions

Planning this AMWC CHINA - AESTHETIC & ANTI-AGING MEDICINE WORLD CONGRESS 2026 route

When and where is AMWC China 2026?

AMWC China 2026 runs October 16 to 18, 2026 at the Wuzhouqing Convention and Exhibition Center in Chengdu, China.

Which product categories should I prioritize on the exhibition floor?

The most active categories at this edition of AMWC China include facial injectables such as neuromodulators and HA fillers, biostimulators, energy-based devices covering laser and IPL platforms, and regenerative or post-procedure skincare. The five exhibitors in this Shared Spotlight each address at least one of those categories.

Who is this Shared Spotlight guide written for?

This guide is written for aesthetic physicians, dermatologists, clinic directors, and procurement leads who are attending AMWC China 2026 and want to plan a deliberate floor route rather than walk the hall at random. It is most useful for buyers who are actively evaluating injectables, energy-based capital equipment, or post-procedure skincare products for their practice or distribution portfolio.

How do I find the booth numbers for these five exhibitors?

Booth assignments are published by the show organizer on the official AMWC China website at amwcchina.com. Floor plans are typically released two to four weeks before the event opens. Check that page and confirm booth numbers before arriving at the venue, as locations can change between the time this guide is published and the show opens.

Are these the only exhibitors worth visiting at AMWC China 2026?

No. This Shared Spotlight covers five companies that purchased placement in this guide. The full exhibitor list at AMWC China 2026 is larger, and buyers with specific needs outside these five categories should consult the official exhibitor directory at amwcchina.com for a complete picture of what is on the floor.